AstraZeneca announces plans to develop research centre at Karolinska Institutet
21st Mar 2013 12:50
AstraZeneca, the FTSE 100 biopharmaceutical giant, on Thursday unveiled plans to create an integrated translational research centre for cardiovascular and metabolic disease and regenerative medicine at medical university Karolinska Institutet's site in Stockholm. The centre will run for an initial
Read moreLondon midday: Selling abates ahead of US data barrage
21st Mar 2013 11:50
UK stocks were near their lows of the day by mid-session, weighed down by the much weaker than forecast manufacturing and services sector data out this morning in the Eurozone. That came ahead of a barrage of macroeconomic statistics which were scheduled for release in the United States this after
Read moreAstraZeneca and Moderna Therapeutics sign deal to develop RNA therapeutics
21st Mar 2013 11:04
FTSE 100-listed biopharmaceutical business AstraZeneca has signed an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise messenger RNA therapeutics for the treatment of cardiovascular, metabolic and renal diseases. Under the terms of the agreement, AstraZeneca will
Read moreAstraZeneca outlines strategy to return to growth
21st Mar 2013 07:14
Biopharmaceutical business AstraZeneca will drive its on-market growth platforms to return to growth as it moves through a period of patent expiries and revenue declines, an update issued by the group has shown. It said that it would progress its Phase II pipeline, which has the potential to doubl
Read moreWednesday broker round-up UPDATE
20th Mar 2013 08:53
Abcam: Canaccord Genuity moves target price from 344p to 358p, but still recommends selling. Antofagasta: Jefferies cuts target price from 1350p to 1100p, while keeping a hold recommendation. ASOS: Cantor Fitzgerald raises target price from 2500p to 2900p reiterating a hold recommendation. Panmure
Read moreLondon close: Stocks trim losses as bank-run fears subside
18th Mar 2013 16:44
After registering sharp declines early on, stock markets across Europe had clawed back losses by the close of trade on Monday, as concerns of a contagious bank run across the Eurozone periphery were eased. Markets suffered a steep sell-off in the morning session after this weekend's controversial b
Read moreAstraZeneca announces job cuts and new research centres
18th Mar 2013 13:04
Biopharmaceutical company AstraZeneca is axing 1,600 jobs as part of plans to invest in new research and development (R&D) centres in the US, UK and Sweden. AstraZeneca said it would reduce its headcount and relocate 2,500 roles to the new centres in Cambridge, UK, Gaithersburg, US, and Mölndal, Sw
Read moreThursday broker round-up UPDATE
14th Mar 2013 07:11
Amara Mining: After having been under review, Cantor Fitzgerald reinitiates coverage with a price target of 81p and a buy recommendation. Antofagasta: Citigroup shifts target price from 990p to 1000p, but retains its sell recommendation. Ashtead Group: Investec raises target price from 475p to 700
Read moreThree AstraZeneca patents ruled invalid in Australia
5th Mar 2013 08:56
Drugs giant AstraZeneca has reported that the Federal Court of Australia has found three patents protecting the company's Crestor treatment to be invalid, after they were challenged by several pharmaceutical firms. The court's decision only affects the patent in Australia and does not have an impa
Read moreLondon close: Footsie hits new five-year high, Sterling slumps
13th Feb 2013 16:36
After a subdued start, London's FTSE 100 index finished with decent gains on Wednesday to set a new five-year high with analysts putting the strong performance down to the weaker pound. Sterling slumped today - down 0.82% against the dollar at 1,5534 - after the Bank of England said that inflation
Read moreFTSE 100 movers: Tullow Oil rises on strong set of results
13th Feb 2013 15:50
Oil and gas group Tullow rose strongly today after posting a four per cent rise in annual pre-tax profits on the back for strong sales and output. Pre-tax profits in 2012 totalled 1.11bn dollars, ahead of analysts' expectations. Irish building materials group CRH was one of the best performers on
Read moreMonday broker round-up UPDATE
11th Feb 2013 07:41
Aquarius Platinum: Deutsche Bank shifts target price from 82p to 83p keeping a buy recommendation. AstraZaneca: JP Morgan cuts target price from 2970p to 2750p and retains an underweight rating. Avation: WH Ireland ups target price from 120p to 140p, while its buy recommendation is kept. Bellway:
Read moreWednesday broker round-up UPDATE
6th Feb 2013 10:12
ARM Holdings: Investec ups target price from 900p to 940p, maintaining its hold recommendation. JP Morgan increases target price from 540p to 625p and retains a neutral rating. UBS moves target price from 900p to 930p, while its neutral rating is reiterated. Espirito Santo raises target price from 8
Read moreFriday broker round-up UPDATE
1st Feb 2013 07:55
Afren: HSBC shifts target price from 190p to 200p, while reiterating an overweight rating. Antofagasta: Exane BNP reduces target price from 1500p to 1350p maintaining an outperform rating. Antrim Energy: Westhouse Securities lowers target price from 70p to 65p and reiterates a buy recommendation.
Read moreLondon close: Stocks fall as focus turns to Friday's US jobs report
31st Jan 2013 16:41
Equities were extending losses on Thursday after yesterday's shock contraction in the States, as markets braced for another busy day on the economic calendar tomorrow. "Traders were unwinding positions earlier on January's phenomenal rally which sees major share markets at multi-year highs," said m
Read more